168 related articles for article (PubMed ID: 10373674)
21. The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence.
Polkowski W; van Lanschot JJ; Ten Kate FJ; Baak JP; Tytgat GN; Obertop H; Voorn WJ; Offerhaus GJ
Surg Oncol; 1995 Jun; 4(3):163-71. PubMed ID: 7582189
[TBL] [Abstract][Full Text] [Related]
22. p53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7.
Symmans PJ; Linehan JM; Brito MJ; Filipe MI
J Pathol; 1994 Jul; 173(3):221-6. PubMed ID: 7931842
[TBL] [Abstract][Full Text] [Related]
23. p53 and Ki-67 in Barrett's carcinoma: is there any value to predict recurrence after circumferential endoscopic mucosal resection?
Lopes CV; Mnif H; Pesenti C; Bories E; Monges G; Giovannini M
Arq Gastroenterol; 2007; 44(4):304-8. PubMed ID: 18317648
[TBL] [Abstract][Full Text] [Related]
24. Malignant progression in Barrett's esophagus: pathology and molecular biology.
Mueller J; Werner M; Siewert JR
Recent Results Cancer Res; 2000; 155():29-41. PubMed ID: 10693236
[TBL] [Abstract][Full Text] [Related]
25. p53 in esophageal adenocarcinoma: a critical reassessment of mutation frequency and identification of 72Arg as the dominant allele.
Chung SM; Kao J; Hyjek E; Chen YT
Int J Oncol; 2007 Dec; 31(6):1351-5. PubMed ID: 17982662
[TBL] [Abstract][Full Text] [Related]
26. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report.
Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A
Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596
[TBL] [Abstract][Full Text] [Related]
27. Immunohistological study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett's esophagus.
Fujii T; Nakagawa S; Hanzawa M; Sueyoshi S; Fujita H; Shirouzu K; Yamana H
Oncol Rep; 2003; 10(2):427-31. PubMed ID: 12579284
[TBL] [Abstract][Full Text] [Related]
28. Molecular evaluation of ablative therapy of Barrett's oesophagus.
Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
[TBL] [Abstract][Full Text] [Related]
29. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus.
Hamelin R; Fléjou JF; Muzeau F; Potet F; Laurent-Puig P; Fékété F; Thomas G
Gastroenterology; 1994 Oct; 107(4):1012-8. PubMed ID: 7523212
[TBL] [Abstract][Full Text] [Related]
30. Detection of the risk of adenocarcinoma in Barrett's esophagus by means of tumor markers (p53 and Ki67).
Trakál E; Guidi A; Butti AL; Trakál JJ; Sambuelli R; Zárate FE
Acta Gastroenterol Latinoam; 2010 Sep; 40(3):211-5. PubMed ID: 21049770
[TBL] [Abstract][Full Text] [Related]
31. [Does the criterium of positivity for the immunohistochemical analysis of p53 in the confirmation of Barrett's dysplasia make any difference?].
Lopes CV; Pereira-Lima JC; Hartmann AA; Tonelotto E; Salgado K
Arq Gastroenterol; 2005; 42(4):233-8. PubMed ID: 16444378
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of p53 protein in Barrett's syndrome with malignant transformation.
Fléjou JF; Potet F; Muzeau F; Le Pelletier F; Fékété F; Hénin D
J Clin Pathol; 1993 Apr; 46(4):330-3. PubMed ID: 8496390
[TBL] [Abstract][Full Text] [Related]
33. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
34. Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry.
Krishnadath KK; Tilanus HW; Alers JC; Mulder AH; van Dekken H
Cytometry; 1994 Feb; 15(2):176-84. PubMed ID: 8168405
[TBL] [Abstract][Full Text] [Related]
35. Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation.
Raouf AA; Evoy DA; Carton E; Mulligan E; Griffin MM; Reynolds JV
Dis Esophagus; 2003; 16(1):17-23. PubMed ID: 12581249
[TBL] [Abstract][Full Text] [Related]
36. Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence.
Hardwick RH; Shepherd NA; Moorghen M; Newcomb PV; Alderson D
Gut; 1994 Jun; 35(6):764-8. PubMed ID: 8020801
[TBL] [Abstract][Full Text] [Related]
37. The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus.
Hamilton SR; Smith RR
Am J Clin Pathol; 1987 Mar; 87(3):301-12. PubMed ID: 3825997
[TBL] [Abstract][Full Text] [Related]
38. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.
Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
Gut; 2013 Dec; 62(12):1676-83. PubMed ID: 23256952
[TBL] [Abstract][Full Text] [Related]
39. Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma.
Brankley SM; Fritcher EG; Smyrk TC; Keeney ME; Campion MB; Voss JS; Clayton AC; Wang KK; Lutzke LS; Kipp BR; Halling KC
Hum Pathol; 2012 Feb; 43(2):172-9. PubMed ID: 21820152
[TBL] [Abstract][Full Text] [Related]
40. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression.
Skacel M; Petras RE; Rybicki LA; Gramlich TL; Richter JE; Falk GW; Goldblum JR
Am J Gastroenterol; 2002 Oct; 97(10):2508-13. PubMed ID: 12385431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]